Epigenetic markers, functional status, and exercise in older adults with myeloid neoplasms
患有髓系肿瘤的老年人的表观遗传标记、功能状态和运动
基本信息
- 批准号:10517787
- 负责人:
- 金额:$ 15.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAccountingActivities of Daily LivingAdultAgeAgingBehavior TherapyBioinformaticsBiologicalBiological MarkersBloodBone MarrowCell divisionCellsChemotherapy-Oncologic ProcedureChronologyComplementControl GroupsDNA MethylationDNA analysisDataDiagnosisDropsElderlyEpigenetic ProcessExerciseGeneral PopulationGeriatricsGrantHematologyIndividualInheritedInternal MedicineInterruptionInterventionLiteratureMalignant NeoplasmsMeasuresMentorsMethylationMorbidity - disease rateMyeloproliferative diseaseOncologyOutpatientsPatient Self-ReportPatientsPeripheralPhasePhysical PerformancePositioning AttributeQuality of lifeRandomized Controlled TrialsReportingResearchResearch PersonnelRiskSamplingSiteTimeTissuesTrainingTranslational Researchagedcancer riskchemotherapyclinically significantepigenetic markerexercise interventionexperiencefrailtyfunctional declinefunctional disabilityfunctional statusgroup interventionhigh risk populationimproved outcomeinstrumental activity of daily livinginterestmHealthmortalitynovelnovel markerolder patientperipheral bloodpreventprospectivepublic health relevancerandomized trialrecruitstandard of carestressor
项目摘要
Over 60% of myeloid neoplasms (MN) are diagnosed in adults aged ≥60 years, and up to 73% of older patients
with MN experience functional impairment before and during chemotherapy. Establishing biomarkers to identify
older patients with MN at risk for functional decline and understanding the mechanisms of decline could guide
interventions to prevent functional decline. DNA methylation (DNAm) age, a novel and promising biomarker of
biological age, may be used to identify older patients at risk for functional decline. DNAm age captures
additional information such as exposures and other stressors that make it a better reflection of biological age
compared to chronological age. Accelerated DNAm age (DNAm age minus chronological age) is associated
with functional decline, frailty, morbidity, and mortality in the general population. Cancer risk is associated with
accelerated DNAm age and chemotherapy leads to profound DNAm changes from pre- to post-chemotherapy
in older adults with cancer. The literature suggests that DNAm age may be a better indicator of risk for
functional decline among older patients with MN than chronological age. DNAm is influenced by exercise which
slows the rate of DNAm age increase over time; exercise is also a promising intervention to prevent functional
decline in older patients with MN. It is not yet known, however, whether exercise can slow the rate of DNAm
age increase or reverse DNAm age in patients with cancer. Understanding exercise-induced epigenetic
changes in older patients with MN, a high risk population, is of great clinical significance. The candidate, Dr.
Kah Poh Loh, is board-certified in internal medicine, hematology, oncology, and geriatrics. As part of her NCI
K99/R00, Dr. Loh has initiated a pilot randomized controlled trial (RCT) to assess the preliminary efficacy of an
mHealth exercise intervention versus control on functional status in older patients with MN receiving outpatient
chemotherapy over 12 weeks. The GEMSSTAR R03 will allow Dr. Loh to leverage this unique study to
investigate 1) to investigate the association of accelerated peripheral blood DNAm age with functional decline
in older adults with MN, 2) to explore exercise-induced epigenetic changes in older patients with MN, and 3) to
explore the correlation between peripheral blood and bone marrow DNAm ages. The R03 will complement Dr.
Loh’s K99/R00 by allowing her to study DNAm age as a novel biomarker of functional decline and the effect of
exercise on DNAm on older adults with cancer. In addition, Dr. Loh will be able to expand her training in
epigenetics, bioinformatics, and translational research in cancer and aging under the guidance of an excellent
mentoring team. Together, Dr. Loh’s R03 and K99/R00 will provide preliminary data for a phase 3 RCT
evaluating the effects of a mHealth exercise intervention on functional decline and epigenetic markers. The
combined training and research plan will also position Dr. Loh to become one of the few geriatric oncology
investigators studying mHealth behavioral interventions and the mechanisms by which these interventions
improve outcomes in older patients with MN.
Over 60% of myeloid neoplasms (MN) are diagnosed in adults aged ≥60 years, and up to 73% of older patients
with MN experience functional impairment before and during chemotherapy. Establishing biomarkers to identify
older patients with MN at risk for functional decline and understanding the mechanisms of decline could guide
interventions to prevent functional decline. DNA methylation (DNAm) age, a novel and promising biomarker of
biological age, may be used to identify older patients at risk for functional decline. DNAm age captures
additional information such as exposures and other stressors that make it a better reflection of biological age
compared to chronological age. Accelerated DNAm age (DNAm age minus chronological age) is associated
with functional decline, frailty, morbidity, and mortality in the general population. Cancer risk is associated with
accelerated DNAm age and chemotherapy leads to profound DNAm changes from pre- to post-chemotherapy
in older adults with cancer. The literature suggests that DNAm age may be a better indicator of risk for
functional decline among older patients with MN than chronological age. DNAm is influenced by exercise which
slows the rate of DNAm age increase over time; exercise is also a promising intervention to prevent functional
decline in older patients with MN. It is not yet known, however, whether exercise can slow the rate of DNAm
age increase or reverse DNAm age in patients with cancer. Understanding exercise-induced epigenetic
changes in older patients with MN, a high risk population, is of great clinical significance. The candidate, Dr.
Kah Poh Loh, is board-certified in internal medicine, hematology, oncology, and geriatrics. As part of her NCI
K99/R00, Dr. Loh has initiated a pilot randomized controlled trial (RCT) to assess the preliminary efficacy of an
mHealth exercise intervention versus control on functional status in older patients with MN receiving outpatient
chemotherapy over 12 weeks. The GEMSSTAR R03 will allow Dr. Loh to leverage this unique study to
investigate 1) to investigate the association of accelerated peripheral blood DNAm age with functional decline
in older adults with MN, 2) to explore exercise-induced epigenetic changes in older patients with MN, and 3) to
explore the correlation between peripheral blood and bone marrow DNAm ages. The R03 will complement Dr.
Loh’s K99/R00 by allowing her to study DNAm age as a novel biomarker of functional decline and the effect of
exercise on DNAm on older adults with cancer. In addition, Dr. Loh will be able to expand her training in
epigenetics, bioinformatics, and translational research in cancer and aging under the guidance of an excellent
mentoring team. Together, Dr. Loh’s R03 and K99/R00 will provide preliminary data for a phase 3 RCT
evaluating the effects of a mHealth exercise intervention on functional decline and epigenetic markers. The
combined training and research plan will also position Dr. Loh to become one of the few geriatric oncology
investigators studying mHealth behavioral interventions and the mechanisms by which these interventions
improve outcomes in older patients with MN.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kah Poh Loh其他文献
Kah Poh Loh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kah Poh Loh', 18)}}的其他基金
Epigenetic markers, functional status, and exercise in older adults with myeloid neoplasms
患有髓系肿瘤的老年人的表观遗传标记、功能状态和运动
- 批准号:
10671527 - 财政年份:2022
- 资助金额:
$ 15.4万 - 项目类别:
A novel mobile health exercise intervention for older patients with myeloid neoplasms
针对老年髓系肿瘤患者的新型移动健康运动干预
- 批准号:
10693908 - 财政年份:2019
- 资助金额:
$ 15.4万 - 项目类别:
A novel mobile health exercise intervention for older patients with myeloid neoplasms
针对老年髓系肿瘤患者的新型移动健康运动干预
- 批准号:
10018836 - 财政年份:2019
- 资助金额:
$ 15.4万 - 项目类别:
A novel mobile health exercise intervention for older patients with myeloid neoplasms
针对老年髓系肿瘤患者的新型移动健康运动干预
- 批准号:
9892057 - 财政年份:2019
- 资助金额:
$ 15.4万 - 项目类别:
A novel mobile health exercise intervention for older patients with myeloid neoplasms
针对老年髓系肿瘤患者的新型移动健康运动干预
- 批准号:
10462854 - 财政年份:2019
- 资助金额:
$ 15.4万 - 项目类别:
A Novel Mobile Health Exercise Intervention for Older Patients with Myeloid Neoplasms
针对老年髓系肿瘤患者的新型移动健康运动干预
- 批准号:
10118259 - 财政年份:2019
- 资助金额:
$ 15.4万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 15.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 15.4万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 15.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 15.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 15.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 15.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 15.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 15.4万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 15.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 15.4万 - 项目类别: